[China National Guideline of Classification, Diagnosis and Treatment for Lung Nodules (2016 Version)].
Qinghua Zhou(Sichuan University), Hong Bu(Sichuan University), Yaguang Fan(Tianjin Medical University General Hospital), Xingyun Wang(Shanghai Jiao Tong University), Ying Wang(Tianjin Medical University General Hospital), Yunchao Huang(North China University of Water Resources and Electric Power), Ning Wu(Regeneron (United States)), Guiqi Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), You‐Lin Qiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiangpeng Zheng(Fudan University), Guozhen Zhang(Huadong Hospital)
Cited by 54
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
A Core/Satellite Multifunctional Nanotheranostic for in Vivo Imaging and Tumor Eradication by Radiation/Photothermal Synergistic Therapy
|Journal of the American Chemical Society|2013|554
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide
|International Journal of Cancer|2006|417
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415